search

Dianthus Therapeutics Inc. (DNTH)

OverviewChartFinancialsStatisticsEarningsInsider transactionsETFsNews

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Relevance *
40
Bank of America Corp DE Takes Position in Dianthus Therapeutics, Inc. $DNTH
Sep 24, 2026

Bank of America Corp DE Takes Position in Dianthus Therapeutics, Inc. $DNTH

Bank of America Corp DE has acquired a new position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH), purchasing 256,833 shares valued at approximately $25 million, representing a 0.47% stake in the company. Despite institutional ownership of 47.53% and a "Moderate Buy" consensus rating from analysts, DNTH shares recently fell by 5.0% after the company reported a quarterly loss that missed consensus estimates. Over the past 90 days, company insiders have sold a significant amount of shares totaling $29.3 million.
Company relevance
100.00%
Company sentiment
Somewhat-Bearish
Overall sentiment
Neutral
Engineers Gate Manager LP Reduces Holdings in Dianthus Therapeutics, Inc. $DNTH
Sep 19, 2026

Engineers Gate Manager LP Reduces Holdings in Dianthus Therapeutics, Inc. $DNTH

Engineers Gate Manager LP significantly reduced its stake in Dianthus Therapeutics (NASDAQ:DNTH) by 47.1% in Q2 2026, selling 10,330 shares. Despite this reduction, institutional investors collectively own 47.53% of the company. Dianthus Therapeutics shares opened down 4.3% at $96.81, and the company reported a quarterly loss of $0.90 per share, missing analyst estimates, though revenue exceeded expectations.
Company relevance
100.00%
Company sentiment
Somewhat-Bearish
Overall sentiment
Somewhat-Bearish